Clinical trials researching the treatment of Spinocerebellar ataxia (SCA) are also examined. Currently recruiting participants, Phase I/Phase II clinical trial NCT05822908 will evaluate the safety and tolerance of four different doses of ASO VO659 in people with SCA1, SCA3, and Huntington's disease. The study will measure concentrations of VO659 in cerebral spinal fluid and blood after single and multiple doses. Small molecule, trehalose, is active with a Phase II/Phase III clinical trial (NCT05490563) to measure its safety and efficacy for the treatment of SCA3. Trehalose has also received FDA orphan drug designation. Another, small molecule drug troriluzole is currently researched in Phase II and Phase III trials (NCT02960893 and NCT03701399) examining its efficacy at 140 mg once daily in subjects with SCA. Troriluzole inhibits voltage gated sodium channels and reduces synaptic glutamate. Unfortunately, results showed no improvement in patients on troriluzole except for a subset with SCA3, which prompted a new drug application to the US FDA. Troriluzole has previously received Fast-Track and Orphan drug designation from the FDA for the treatment of SCA. Lastly, Sclnow biotechnology is not yet recruiting but will be researching their Umbilical Cord Mesenchymal Stem Cell therapy (UC-MSC) for patients with spinocerebellar ataxia. The Phase II clinical trial (NCT03378414) will not only verify safety and efficacy but will also research the possible mechanisms of UC-MSC therapy in SCA.